To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Abion Inc
- Target Recruit Count
- 178
- Registration Number
- NCT05541822
- Locations
- πΊπΈ
Cancer Care of North Florida, PA (Lake City Cancer Care, LLC) - Medical Oncology, Lake City, Florida, United States
πΊπΈMid Florida Center, Orange City, Florida, United States
πΊπΈThe Henry Ford Cancer Institute, Detroit, Michigan, United States
To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Solid Tumor
- Interventions
- Other: High-fat meal (over 900 kcal)Drug: ABN401 (investigational product)
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Abion Inc
- Target Recruit Count
- 25
- Registration Number
- NCT05248074
- Locations
- π°π·
Chungbuk National University Hospital, Cheongju-si, Seowon-gu, Korea, Republic of
To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: ABN401- Escalation PhaseDrug: ABN401- Expansion Phase
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Abion Inc
- Target Recruit Count
- 24
- Registration Number
- NCT04052971
- Locations
- π¦πΊ
ST George Private Hospital, Kogarah, New South Wales, Australia
π¦πΊSydney Southwest Private Hospital, Liverpool, New South Wales, Australia
π¦πΊScientia Clinical Research, Randwick, New South Wales, Australia
Β© Copyright 2025. All Rights Reserved by MedPath